[1] HANAHAN D,WEINBERG RA.Hallmarks of cancer:the next generation［J］.Cell,2011,144(5):646-674.
[2] WANG W,LI Y,LIN K,et al.Progress in building clinically relevant patient-derived tumor xenograft models for cancer research［J］.Animal Model Exp Med,2023,6(5):381-398.
[3] WU J,ZHENG Y,TIAN Q,et al.Establishment of patient-derived xenograft model in ovarian cancer and its influence factors analysis［J］.J Obstet Gynaecol Res,2019,45(10):2062-2073.
[4] JIN J,YOSHIMURA K,SEWASTJANOW-SILVA M,et al.Challenges and prospects of patient-derived xenografts for cancer research［J］.Cancers(Basel),2023,15(17):4352.
[5] SITTITHUMCHAREE G,SUPPRAMOTE O,VAETEEWOOTTACHARN K,et al.Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity［J］.Hepatology,2019,70(5):1614-1630.
[6] SUGISAWA N,MIYAKE K,HIGUCHI T,et al.High incidence of lymph-node metastasis in a pancreatic-cancer patient-derived orthotopic xenograft(PDOX) NOG-mouse model［J］.Anticancer Res,2022,42(2):739-743.
[7] DOYLE K,HASSAN AE,SUTTER M,et al.Development of a simple and reproducible cell-derived orthotopic xenograft murine model for neuroblastoma［J］.In Vivo,2024,38(2):531-538.
[8] STRIBBLING SM,BEACH C,RYAN AJ.Orthotopic and metastatic tumour models in preclinical cancer research［J］.Pharmacol Ther,2024,257:108631.
[9] ZHANG Y,LEE SH,WANG C,et al.Establishing metastatic patient-derived xenograft model for colorectal cancer［J］.Jpn J Clin Oncol,2020,50(10):1108-1116.
[10] KUDCHADKAR RR,LOWE MC,KHAN MK,et al.Metastatic melanoma［J］.CA Cancer J Clin,2020,70(2):78-85.
[11] NASCENTES MELO LM,KUMAR S,RIESS V,et al.Advancements in melanoma cancer metastasis models［J］.Pigment Cell Melanoma Res,2023,36(2):206-223.
[12] XU W,ZHAO ZY,AN QM,et al.Comprehensive comparison of patient-derived xenograft models in hepatocellular carcinoma and metastatic liver cancer［J］.Int J Med Sci,2020,17(18):3073-3081.
[13] STRUDER D,MOMPER T,IRMSCHER N,et al.Establishment and characterization of patient-derived head and neck cancer models from surgical specimens and endoscopic biopsies［J］.J Exp Clin Cancer Res,2021,40(1):246.
[14] CHAVES P,GARRIDO M,OLIVER J,et al.Preclinical models in head and neck squamous cell carcinoma［J］.Br J Cancer,2023,128(10):1819-1827.
[15] MURAYAMA T,GOTOH N.Patient-derived xenograft models of breast cancer and their application［J］.Cells,2019,8(6):621.
[16] JUNG J,JANG K,JU JM,et al.Novel cancer gene variants and gene fusions of triple-negative breast cancers (TNBCs) reveal their molecular diversity conserved in the patient-derived xenograft (PDX) model［J］.Cancer Lett,2018,428:127-138.
[17] TEW BY,LEGENDRE C,SCHROEDER MA,et al.Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones［J］.Neuro Oncol,2020,22(1):70-83.
[18] SATO K,NIIDA A,MASUDA T,et al.Multiregion genomic analysis of serially transplanted patient-derived xenograft tumors［J］.Cancer Genomics Proteomics,2019,16(1):21-27.
[19] WANG J,XING B,LIU W,et al.Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis［J］.Theranostics,2019,25;9(12):3485-3500.
[20] DUSTIN D,GU G,BEYER AR,et al.RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer［J］.Br J Cancer,2021,124(1):191-206.［21］ LIAO YM,WANG YH,HUNG JT,et al.High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer［J］.Breast Cancer Res,2021,23(1):5.
[22] KOCH C,KUSKE A,JOOSSE SA,et al.Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity［J］.EMBO Mol Med,2020,12(9):e11908.
[23] DIMITROV-MARKOV S,PERALES-PATON J,BOCKORNY B,et al.Discovery of new targets to control metastasis in pancreatic cancer by single-cell transcriptomics analysis of circulating tumor cells［J］.Mol Cancer Ther,2020,19(8):1751-1760.
[24] CHEN A,NEUWIRTH I,HERNDLER-BRANDSTETTER D.Modeling the tumor microenvironment and cancer immunotherapy in next-generation humanized mice［J］.Cancers (Basel),2023,15(11):2989.
[25] LI Z,WANG J,WANG Z,et al.Towards an optimal model for gastric cancer peritoneal metastasis:current challenges and future directions［J］.Ebio Medicine,2023,92:104601.
[26] LEFLEY D,HOWARD F,ARSHAD F,et al.Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts［J］.Breast Cancer Res,2019,21(1):130.
[27] 王洁,赵菊梅,魏晓丽,等.基于PDX模型的胃癌转移相关基因研究进展［J］.中国实验动物学报,2019,27(05):663-667.WANG J,ZHAO JM,WEI XL,et al.Research progress of gastric cancer metastasis related genes based on PDX model ［J］.Chinese Journal of Experimental Animals,2019,27(05):663-667.
[28] SHIBUYA N,KAKEJI Y,SHIMONO Y.MicroRNA-93 targets WASF3 and functions as a metastasis suppressor in breast cancer［J］.Cancer Scil,2020,111(6):2093-2103.
[29] YANG H,LI X,MENG Q,et al.CircPTK2(hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer［J］.Mol Cancer,2020,19(1):13.
[30] KAUR K,KOZLOWSKA AK,TOPCHYAN P,et al.Probiotic-treated super-charged NK cells efficiently clear poorly differentiated pancreatic tumors in Hu-BLT mice［J］.Cancers (Basel),2019,12(1):63.
[31] LIU G,FAN X,CAI Y,et al.Efficacy of dendritic cell-based immunotherapy produced from cord blood in vitro and in a humanized NSG mouse cancer model［J］.Immunotherapy,2019,11(7):599-616.
[32] PYO KH,KIM JH,LEE JM,et al.Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models［J］.Lung Cancer,2019,127:112-121.
[33] KLEINMANNS K,GULLAKSEN SE,BREDHOLT G,et al.Humanized ovarian cancer patient-derived xenografts for improved preclinical evaluation of immunotherapies［J］.Cancers(Basel),2022,14(13):3092.
[34] LI Z,ZHENG W,WANG H,et al.Application of animal models in cancer research:Recent progress and future prospects［J］.Cancer Manag Res,2021,13:2455-2475.
[35] HIROSHIMA Y,ZHANG Y,ZHANG N,et al.Establishment of a patient-derived orthotopic Xenograft(PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern［J］.PLoS One,2015,10(2):e0117417.
[36] CUI Y,RAN R,DA Y,et al.The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment［J］.J Cell Mol Med,2024,28(9):e18374.
[37] LONG Z,LU Y,LI M,et al.Predicting chemosensitivity based on mini patient-derived xenografts in osteosarcoma patients:A retrospective study［J］.J Cancer Res Ther,2023,19(1):71-77.
[38] ZHOU S,LU J,LIU S,et al.Role of the tumor microenvironment in malignant melanoma organoids during the development and metastasis of tumors［J］.Front Cell Dev Biol,2023,11:1166916.
[39] SPROUFFSKE K,KERR G,LI C,et al.Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models［J］.Comput Struct Biotechnol J,2020,18:323-331.
[40] LIU Y,WU W,CAI C,et al.Patient-derived xenograft models in cancer therapy:technologies and applications［J］.Signal Transduct Target Ther,2023,8(1):160.
[41] KONSTANTINOPOULOS PA,MATULONIS UA.Current status and evolution of preclinical drug development models of epithelial ovarian cancer［J］.Front Oncol,2013,3:296.
[42] DEBORD LC,PATHAK RR,VILLANEUVA M,et al.The chick chorioallantoic membrane(CAM) as a versatile patient-derived xenograft(PDX) platform for precision medicine and preclinical research［J］.Am J Cancer Res,2018,8(8):1642-1660.
[43] ABDOLAHI S,GHAZVINIAN Z,MUHAMMADNEJAD S,et al.Patient-derived xenograft (PDX) models,applications and challenges in cancer research［J］.J Transl Med,2022,20(1):206.
[44] LANDUZZI L,PALLADINI A,CECCARELLI C,et al.Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft［J］.Sci Rep,2021,11(1):1563.